Item 7.01 Regulation FD Disclosure.
The information in this report furnished pursuant to Items 2.02 and 7.01 shall
not be deemed "filed" for the purposes of Section 18 of the Securities and
Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to
the liabilities of that section. It may only be incorporated by reference in
another filing under the Exchange Act or the Securities Act of 1933, as amended,
if such subsequent filing specifically references the information furnished
pursuant to Items 2.02 and 7.01 of this report.
At an investor conference on January 9, 2013, Sarepta Therapeutics, Inc.
disclosed that its cash balance as of December 31, 2012 was approximately $187
million.
Add
SRPT to Portfolio
Set Alert
Email to a
Friend